introduction
The inhibition of rapidly accelerated fibrosarcoma kinase B (BRAF), a serine/threonine-protein kinase in the RAS pathway of cell proliferation, was identified about a decade ago as a fruitful target for cancer treatment. With the finding by the Sanger institute that 59% of melanoma cell lines and 67% of melanoma clinical specimens harbored BRAF mutation [1] , and the subsequent discovery that this mutation was seen in 50% of metastatic melanoma [2] , the race was on to harness this discovery for clinical utility. As it turned out, 90% of BRAF mutant melanomas involve a glutamic acid to valine substitution at position 600 (V600E) [3] , which results in sustained activation of the mitogen-activated protein kinase (MAPK) pathway in the absence of any growth factor signal. This finding allowed the development of targeted therapy towards this specific mutation, and the recent development of BRAF-targeted agents for the treatment of advanced melanoma has produced unprecedented response rates in several clinical trials. Figures 1 and 2 , respectively, illustrate such a response on cutaneous metastatic melanoma in a patient at baseline and then following 36 weeks of treatment with GSK2118436/GSK1120212. Vemurafenib received Food and Drug Administration (FDA) approval in August 2011 after the results of a phase III trial demonstrated a survival benefit, but with a very short follow-up of the trial cohort in June 2011 [4] . Many other small-molecule inhibitors targeting the RAS pathway are currently under development [5] . With FDA approval of vemurafenib, access to this agent will be expanded and more clinical experience will be gained.
One of the interesting observations during these studies was a number of cutaneous effects of the drugs. Some are proliferative processes and others are more typical drug sideeffects. Known dermatologic side-effects of vemurafenib, for example, include cutaneous squamous cell carcinomas (SCCs) and keratoacanthomas, as well as photosensitivity [6] . Although SCCs were also observed with the non-selective rapidly accelerated fibrosarcoma kinase (RAF) inhibitor, sorafinib [7, 8] , clinical experience with dermatologic effects of selective BRAF inhibitors remains quite limited, and dermatologists will be seeing these patients both for their melanomas but also for the multiple cutaneous events. To better clarify these dermatologic side-effects, which are often not reported in detail within oncology study reports or drug labels, a retrospective chart review of 53 patients undergoing therapy with either the BRAF-inhibitor vemurafenib, or the combination therapy of GSK2118436 (BRAF inhibitor) and GSK112021 [mitogen-activated protein kinase (MEK) inhibitor] was conducted.
design
The study utilized an institutional review board (IRB) approved retrospective record review of 53 patients receiving some form of BRAFinhibitor therapy at the Massachusetts General Hospital for 4-92 weeks.
Patients were evaluated at baseline with full body skin exams (FBSE) by 1 of 2 dermatologists before receiving BRAF-inhibitor therapy. After beginning treatment with the BRAF inhibitor, patients were followed at 4 weeks, then every 8-12 weeks thereafter with repeat FBSE by the same dermatologists at the same clinic. New skin lesions were identified based on clinical appearance. Skin lesions with suspected malignant potential were biopsied and confirmed by histologic examination. The charts of these patients were reviewed retrospectively, and the morphology and timing of these cutaneous events were recorded.
results
We examined 53 patient records that received treatment with vemurafenib 960 mg BID (also known as RO5185426 or PLX4032) or combination therapy with GSK2118436 150 mg BID/GSK1120212 2 mg daily (a BRAF inhibitor and MEK inhibitor, respectively). Twenty records were excluded from this review because 4 only had baseline evaluation at the time of review, 1 never received BRAF-inhibitor therapy following baseline exam, and 15 never reported for follow-up FBSE. Of the remaining 33 charts, 15 had been treated with vemurafenib and 18 had been treated with GSK2118436/GSK1120212. All patients received the full treatment dose. The mean age of these patients was 56.8 years and they were being treated primarily for melanoma, although there were three patients enrolled in three studies of GSK2118436/GSK1120212 in the treatment of V600E mutant salivary gland cancer, colon cancer, and large cell neuroendocrine carcinoma of the lung. Of the combined group of 33 patients receiving some form of BRAF inhibitor, 13 (39.4%) developed photosensitivity, 10 (30.3%) developed actinic keratoses (AKs), 10 (30.3%) developed warts, 6 (18.2%) developed SCC, 2 (6.1%) developed multiple SCC, 4 (12.1%) developed milia, 4 (12.1%) developed a follicular papulopustular rash, and 3 (9.1%) developed basal cell carcinoma (BCC; Table 1 ). Other cutaneous side-effects included erythema nodosum, genital herpes reactivation, hand-foot skin reaction, cysts, psoriasis flare, urticaria, and pruritus. Table 1 ). The mean and median age of vemurafenib treated patients were 55.8 and 57 years, respectively with a male to female ratio of 3:2.
Of the 18 patients taking GSK2118436/GSK1120212, 3 (16.7%) experienced photosensitivity, 4 (22.2%) developed AKs, 3 (16.7%) developed warts, 2 (11.1%) developed SCC, none developed multiple SCC, none developed milia, 3 (16.7%) developed a follicular papulopustular rash, and 1 (5.5%) developed BCC ( Table 1 ). The mean and median age of GSK2118436/GSK1120212 treated patients were 58.3 and 57.5 years, respectively with a male to female ratio of 4:2.
The median time to first detection of photosensitivity, AK, SCC, and warts was relatively brief in both sets of patients, usually within the first 1-6 months of therapy ( Table 2 ).
None of the described dermatologic side-effects required dose interruptions, modifications, or discontinuation of therapy. SCC and BCC were managed with surgical excision; AKs and warts were managed with cryotherapy; photosensitivity was managed with sun avoidance and photoprotection; and milia and papulopustular rashes did not require specific treatment.
discussion
Patients taking BRAF inhibitors developed a multitude of cutaneous findings. Although the number of patients examined in each group was relatively small, some trends were already apparent. Some previously reported cutaneous reactions like photosensitivity, SCC, and AK were observed in these groups, and some other dermatologic lesions such as warts, milia, and follicular papulopustular rashes were observed as well. In general, the timing of onset for these findings appears shorter in the vemurafenib group and delayed in the GSK2118436/ GSK1120212 group.
Previously reported findings of photosensitivity with vemurafenib [4] were observed in this study. Photosensitivity was by far the most frequently reported cutaneous event overall and was more common in patients treated with vemurafenib. Patients undergoing treatment with any BRAF inhibitor should be counseled strictly to practice sun protection measures.
SCCs were also observed in patients from both drug treatment groups; however, they were seen at greater frequency and earlier in patients taking vemurafenib (Figure 3 and supplementary Figure S1 , available at Annals of Oncology online). Previously reported rates of SCC were 18% with vemurafenib and 8% with GSK2118436 monotherapy [4, 9] . In addition, the histologic characterization of these tumors suggested that they are generally more aggressive than previously described [10, 11] . The oncogenesis of cutaneous SCC in general is multifactorial. Different mutations have been identified and SCC oncogenesis involves p53 mutations, mutation or loss of the P16INK4 tumor suppressor gene, RAS activation, and complex cytogenetic aberrations [12] . About 50% of SCC show a mutation in P53 [13] , and mutant RAS is identified in 22% of SCC [14] .
A recent study of SCC and kerato-acanthomas (KAs) developing in patients taking vemurafenib highlighted the importance of RAS mutations in the pathogenesis of these lesions [15] . Of the 35 specimens analyzed, 21 (60%) harbored RAS mutations and the most prevalent mutation was HRAS Q61L [15] . The investigators further demonstrated paradoxical MAPK signaling in HRAS Q61L murine cell line B9 upon exposure to vemurafenib [15] . This finding was modeled in vivo; and mice exposed to the HRAS Q61L mutation-inducing agents 7,12-dimethylbenz(a)anthracene and 12-Otetradecanoylphorbol-13-acetate developed tumors faster when concomitantly given PLX4720 (vemurafenib analog) relative to controls [15] .
In addition, human papilloma virus (HPV) has been strongly linked to cutaneous SCC in epidermodysplasia verruciformis patients [16] and solid organ transplant recipients [17, 18] . In solid organ transplant recipients, 80% of cutaneous SCC had HPV DNA detected in high levels [19] [20] [21] [22] . Also, HPV16 was present in 74% of digital and periungal SCC [23] . However, elsewhere in the skin, and in immunocompetent individuals, detection of HPV in cutaneous SCC is variable at 27-70% [17, 21, 24] . A recent study specifically found HPV DNA from beta papillomavirus type 2 associated more frequently with cutaneous SCC tissue samples relative to the surrounding skin and also found cutaneous SCC more likely to harbor multiple HPV types relative to surrounding skin [25] . Combined, the role of HPV in extragenital cutaneous SCC remains a matter of controversy, but may well have a role in the presence of other factors. The mechanism by which BRAF inhibition drives appearance of SCC remains to be determined, however, the data about HPV and immunosuppression raised some important hypotheses. The first proposal requires a wild-type (WT) BRAF and an activated RAS. In this scenario, RAF inhibitors bound to BRAF cause a RAS-driven BRAF-rapidly accelerated fibrosarcoma kinase C (CRAF) dimerization and cross activate the pathway through CRAF [26, 27] . The second mechanism similarly involves an activated RAS (mutated or activated upstream by EGFR) and transactivation of a BRAF inhibitor bound BRAF/BRAF homodimer, or a BRAF inhibitor bound BRAF/CRAF heterodimer. This activation is dose dependent and occurs at low concentrations of BRAF inhibitor [27] . Both pathways require RAS activation and WT BRAF and result in MEK/ERK activation. Indeed, in vitro studies demonstrate WT BRAF and WT RAS or WT BRAF, and mutant RAS cell lines hyperproliferate upon treatment with BRAF inhibitors [26] . With mounting evidence that BRAF inhibitors activate the MAPK pathway in cells that lack a BRAF mutation [26] [27] [28] , the SCCs that present precipitously with BRAF-inhibitor therapies are likely driven by this pathway in some manner. In addition, an unrelated antitrypanosomal drug, suramin, inhibits RAF and has resulted in SCC and KA as well [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . Interestingly, prior studies of the multikinase inhibitor sorafenib report that SCC occurs in 6-7% of patients at a median time of 6.7 months [32] . Sorafenib is currently FDA approved for renal cell carcinoma, however, it failed to demonstrate activity against melanoma cells despite RAF inhibitor activity. Although sorafenib is a multikinase inhibitor affecting multiple serine/threonine kinases and tyrosine kinases including RAF, vascular endothelial growth factor, platelet-derived growth factor subunit B, C-KIT, RET, and soluble fms-like tyrosine kinase 3 [33] , its action on BRAF was too weak to demonstrate clinical efficacy in melanoma. However, the finding of SCC in patients treated with this drug, albeit at a lower rate and after a longer period of time, is likely due to its RAF inhibitory effect. A recent observational study reported SCC in 5 of the 15 patients taking vemurafenib for at least 1 month [34] . Phase 3 trials of vemurafenib reported a comparatively higher rate of SCC or KA among 18% of patients treated [4] . Phase I trials of vemurafenib reported a median time of 8 weeks to the development of SCC, a much quicker onset than seen with sorafenib [10] . Vemurafenib is a much more potent and specific BRAF inhibitor relative to sorafenib, and this conveniently follows the clinical observations. There has been speculation that the addition of MEK inhibitor in the presence of BRAF inhibitor would eliminate this increased the appearance of SCC and indeed phase I studies of GSK2118436 (BRAF inhibitor) and GSK1120212 (MEK inhibitor) in combination reported no SCC [35] . Unfortunately, we did observe 2 SCC (one SCCIS and one invasive SCC) of 18 patients treated with this regimen. This observation comes from a relatively small sample, however, it does follow the theory that the presence of a MEK inhibitor is protective against SCC (Table 1) .
In contrast to SCC, common warts are a frequent and relatively benign finding in the general population. HPV is known to be the causative agent with HPV 1, 2, 4, 27, 57, and 63 being the most frequently implicated [36] . The mechanism for the high occurrence of warts (supplementary Figure S2 , available at Annals of Oncology online) and the HPV subtype of the warts observed in patients undergoing treatment with BRAF inhibitors remains to be seen. Interestingly, the dermatopathology of some lesions biopsied in our patient sample showed overlapping features of warts and SCC (Figure 4) . Currently, the role of HPV in the SCCs observed in these patients remains undetermined. It is known that HPV DNA is more prevalent on sun exposed skin due to UV immunosuppression increasing HPV infection [37] [38] [39] . In addition, RAF inhibitors administered to mice result in hyperkeratosis through increased MEK activation [27] , and this signal in the presence of HPV could theoretically promote the appearance of verruca. In vitro studies of several HPV types demonstrate HPV protein E6 that reduces DNA repair of UVB damage [40] Also, in cervical cancer, the E6 gene of high-risk HPV types has been shown to induce degradation of p53 [40] . The activation of RAS in the presence of UV or HPV interference with the tumor suppressor P53 could promote a genetic environment favorable to the proliferation of HPV and SCC. Although immunosuppression has been associated with warts, vemurafenib has demonstrated minimal effects on the function of lymphocytes in vitro [41] . The immune impact of the GSK2118436 (BRAF inhibitor) and GSK1120212 (MEK inhibitor) is less well understood, however, immunosuppression has not been published in relation to these agents at this time. In our observation, the incidence of warts was decreased with GSK2118436 (BRAF inhibitor) and GSK1120212 (MEK inhibitor) relative to vemurafenib as well, further reinforcing a RAF driven origin for these lesions. HPV typing of the warts and SCCs that develop in the context of BRAF inhibitors should be considered in future investigations.
AKs are well known precursors to SCC and not surprisingly, their appearance was increased in the presence of BRAF inhibitors as well. Again the presence of MEK inhibitor appears to be potentially protective, as we observed almost half as many AKs in GSK2118436 (BRAF inhibitor) and GSK1120212 (MEK inhibitor) relative to vemurafenib. P53 mutations are frequently found in AK [12] , and HPV 38 has been described in 43% of AK [37] . These factors may contribute to their appearance in the context of activated RAS. In general, AKs are well-known precursor lesions and ∼10% progress to SCC [42] ; however, the behavior and progression to SCC rate of AK in the context of BRAF inhibition requires further study, and aggressive management with cryotherapy is recommended.
We observed milia in the context of only patients treated with vemurafenib, and in over a quarter of patients treated with this agent. Milia resemble miniature infundibular cysts [43] , and one additional patient treated with vemurafenib original articles Annals of Oncology developed an eruptive group of infundibular occlusion cysts on the buttocks as well. Follicular infundibular cysts and milia have also been seen with sorafenib [8] , and this taken with murine models of hyperkeratosis in the presence of RAF inhibition [27] could imply a MEK/ERK driven pathogenesis of these lesions. Milia and infundibular cysts have also been documented with EGFR inhibitors gefitinib and matuzamab [8] , suggesting there may also be an upstream role of the MAPK pathway in disorders of keratinization.
The hand-foot skin reaction (HFSR) presents as painful hyperkeratosis, erythema, and swelling of the palms and soles. Clinically distinct from the palmar-plantar erythrodysesthesia or hand-foot syndrome, HFSR has been seen in up to 60% of patients treated with sorafenib or sunitinib [44] . These multikinase inhibitors work on multiple pathways including c-KIT, vascular endothelial growth factor receptor, plateletderived growth factor receptor, and Flt3 receptor tyrosine kinases. Sorafenib is also a non-selective RAF inhibitor. We saw only one case of HFSR in association with vemurafenib and this may imply pathways outside of RAF in the etiology of HFSR.
A papulopustular follicular eruption was noted in one patient taking vemurafenib and three patients taking GSK2118436 (BRAF inhibitor) and GSK1120212 (MEK inhibitor; supplementary Figure S3 , available at Annals of Oncology online). Similar phenomena have been observed in patients taking EGFR inhibitors including cetuximab, panitumimab, erlotinib, and gefitinib [45] . The mechanism for this reaction is unknown; however, disruption of the physiologic signaling of EGFR in the follicles is suspected. The action of vemurafenib or GSK2118436 (BRAF inhibitor) and GSK1120212 (MEK inhibitor) downstream from EGFR could also disrupt this process. Interestingly, experience with another experimental MEK inhibitor, selumetinib, noted a papulopustular rash in 100% of the 11 patients taking the drug [46] . This may implicate the MEK inhibitor portion of GSK2118436/GSK1120212 in this reaction.
Overall, cutaneous findings in patients undergoing treatment with BRAF inhibitors are plentiful, and close dermatologic support with frequent FBSE is recommended to ensure early identification of non-melanoma skin cancer. Photosensitivity, warts, AKs, and SCC were most frequently found in this group of 33 patients and may be directly related to the therapeutic mechanism. These findings were all seen with greater frequency and earlier in patients taking vemurafenib. The development of these lesions in the presence of BRAF inhibition with and without MEK inhibition provides multiple avenues for further study regarding the molecular biology of these dermatological phenomena. acknowledgments PLM, MBAP, and ABK were involved with the literature search, figures, study design, data collection, data analysis, data interpretation, writing, and manuscript review. SK selected and prepared histopathologic slide figures and legends and carried out manuscript review. KTF was involved with study design, data analysis, and editorial review of the manuscript. DPL was involved in data collection and interpretation.
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